Table and links to the replies received from member states and regional offices to the SCP.
Country/Region | Section 1: General | Section 2: Private and/or non-commercial use | Section 3: Experimental use and/or scientific research | Section 4: Preparation of medicines | Section 5: Prior use | Section 6: Use of articles on foreign vessels, aircraft and land vehicles | Section 7: Acts for obtaining regulatory approval from authorities | Section 8: Exhaustion of patent rights | Section 9: Compulsory licensing and/or government use | Section 10: Exceptions and limitations related to farmers' and/or breeders' use of patented inventions | Section 11: Other exceptions and limitations | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
x | x | x | x | x | x | x 25 |
x | x | x | – | ||
Algeria |
x | x | x | – | x | x | – | x | x | – | – | |
Argentina |
x | x | x | x | x | x | x | x | x | * 33 | x | |
Armenia |
x | x | x | x | x | x | – | x | x 1 | – | – | |
Australia |
x 2 | – | x | x | x | x | – | – | ||||
Austria |
x | x | x | – | x | x | x | x | x | x | – | |
Azerbaijan |
x | x | x | x | x | x | – | x | x | – | – | |
Bangladesh |
x | – | – | – | * 34 | x | – | – | x1 | – | – | |
x | x | x | x | x | x | – | x | x1 | – | x | ||
Bhutan |
x | – | x | – | x | x | – | x | x | – | – | |
Bosnia and Herzegovina |
x | x | x | x | x | x | x | x | x | x | – | |
Brazil |
x | x | x | x | x | x | x | x | x | 3 | x | |
x | x | x | x | x | x | x | x | x | x | – | ||
Burkina Faso |
x | – | x | – | x | x | – | x | x | x | – | |
Canada |
x | – | x | – | x | x | x | x | x | – | x 20 | |
Chile |
x | – | – | – | – | 4 | x | x | x 1 | – | x | |
China
Hong Kong China |
x | x | x | – | x | x | x | x | x | – | – | |
x | x | x | x | x | x | – | – | x | – | x | ||
Congo |
x | – | x | – | – | – | – | – | x | – | – | |
Costa Rica |
x | x | x | – | x | x5 | x | x | x | – | – | |
Croatia 1 2 update |
x | x | x | x | x | x | x | x | x | x | – | |
Cyprus |
x | x | x | x | – | – | – | x | x | – | – | |
Czech Republic |
x | x | x | x | x | x | x | x | x 1 | x | – | |
Democratic People's Republic of Korea |
x | *6 |
x | x6 | x7 |
x | – | – | x1
|
– | – | |
Denmark |
x | x | x | x | x | x | x | x | x 1 | x | – | |
Djibouti |
x | – | – | – | – | – | – | – | x 1 | – | * 23 | |
Dominican Republic |
x | x | x | – | x | – | x | x | x | – | – | |
El Salvador [Note EN ES] |
x | x | x | – | x | x | x | x | x 1 | – | – | |
Finland |
x | x | x | x | x | x | x | x | x | x | – | |
France |
x | x | x | x | x | x | x | x | x | x | – | |
Gambia |
x | – | – | – | – | x | – | x | x | – | – | |
Georgia |
x | x | – | – | x | x | – | x | x 35 | * 36 | – | |
Germany |
x | x | x | x | x | x | x | x | x | x | x | |
Greece |
x | x | x | x | x | x | x | x | x | x | – | |
Honduras |
x | x | x | – | – | – | – | x | x | – | – | |
Hungary |
x | x | x | x | x | x | x | x | x 1 | – | – | |
x | x | x | – | x | x | x | x | x | *37 | x | ||
Indonesia |
x | – | x | – 9 | x | – | – | – | x | – | – | |
Israel |
x | x | x | – | x | x | x | x 14 | x | *16 | x | |
Italy |
x | x | x | x | x | – | x | x | x | 10 | – | |
Jamaica |
x | – | – | – | – | – | – | – | – | – | – | |
Japan 1 2 update |
x | x | x | x | x | x | x | x | x 1 | – | – | |
x | x | x | – | – | – | x | x | x | – | – | ||
x | x | x | – | x | x | x | x | x | x | x | ||
Kyrgyzstan |
x | – | x | – | x | x | – | – | x | – | – | |
Latvia |
x | x | x | x | x | x | x | x | x | x | – | |
Lithuania |
x | x | x | x | x | x | x | x | x | x | – | |
Madagascar |
x | x | – | – | x | x | – | x | x | – | – | |
Malaysia |
x | x | x | – | x | x | x | – | x | – | – | |
Mauritius |
x | – | x | – | x | – | – | x | x | – | – | |
Mexico 1 2 update |
x | x | x | – | x | x | x | x | x 1 | x | – | |
Monaco |
x | – | – | – | – | – | – | – | x 1 | – | – | |
Morocco |
x | x | x | x | x | x | * 11 | x | x | – | – | |
Netherlands |
x | x | x | – | x | x | x | x | x | x 12 | – | |
New Zealand |
x | – | x | – | *13 | x | x | x 14 | x | – | – | |
Norway |
x | x | x | x | x | x | x | x | x | x | x | |
Oman |
x | x | x | – | x | x | x40 | x | x | x | x | |
Pakistan |
x | – | x | – | x | x | x | x | x | – | x | |
Peru |
x | x | x | – | x | x | x | x | x 1 | – | – | |
Philippines 1 2 update |
x | x | x | x | x | x | x | x 15 | x | – | – | |
Poland |
x | x | x | x | x | x | x | x | x | x | – | |
Portugal |
x | x | x | x | x | x | x | x | x | x | 17 | |
Qatar |
x | – | x | – | x | – | x 26 |
x 27 |
x | – | – | |
Republic of Korea |
x | x | x | x | x | x | x | – | x | * 18 | – | |
x | x | x | x | x | x | – | x | x | x | – | ||
Romania |
x | x | x | – | x | x | * 29 |
x | x | – | – | |
Russian Federation RU EN |
x | x | x | x | x | x | – | x | x | – | x | |
Sao Tome and Principe EN ES |
x | – | x | – | x | x | – | x | x | – | x | |
Saudi Arabia |
x | x | x | – | x | x | – | – | x | x | – | |
Serbia |
x | x | x | x | x | x | – | x | x 1 | x | – | |
Slovakia |
x | x | x | x | x | x | x | x | x 1 | x | – | |
South Africa |
x | x | – | – | * 28 |
x | x | x | x | x | – | |
Spain |
x | x | x | x | x | x | x | x | x 1 | x 11 | x | |
Sri Lanka |
x | x | x | – | x | x | – | x | x | – | – | |
Sudan |
x | – | – | *38 | x | – | – | x | x 1 | * 39 | x | |
Sweden |
x | x | x | x | x | x | x | x | x 1 | x | – | |
Switzerland |
x | x | x | – | x | x | x | x | x 1 | x | x | |
Tajikistan |
x | x | x | x | x | x | – | x | x | x | – | |
Thailand |
x | – | x | x | x | x | x | x | x | – | – | |
Turkey |
x | x | x | x | x | x | x | x | x 1 | – | – | |
Uganda |
x | x | x | – | x | x | – | x | x | x 31 | – | |
Ukraine |
x | x | x | – | x | x | x | x | – | x | ||
x | x | x | x | x | x | x | x | x | x | x | ||
United Republic of Tanzania |
x | x | x | – | – | x | – | x | x | – | – | |
United States of America |
x | – | x | – | x | x | x | x | x | * 19 | * 20 | |
Viet Nam |
x | x | x | x | x | x | x | x | x | x | – | |
Zambia 1 2 update |
x | – | – | – | x | x | x41 | – | x | – | – | |
Zimbabwe |
x | x | x | – | – | x | – | x | x | – | – | |
Eurasian Patent Office (EAPO) |
x | x | x | x | x | x | – | 21 | x 22 | – | – |
1. Only compulsory licensing, no government use exception.
2. There is no statutory provision related to private and/or non-commercial use exception. However, it is considered that a non-commercial use defense may arise under common law.
3. Only exception relating to the breeders' use of patented inventions, no exception relating to the farmers' use of patented inventions.
4. There is no statutory exception related to the use of articles on foreign vessels, aircrafts and land vehicles. However, Article 5ter of the Paris Convention and Article 27 of the Chicago Convention applies.
5. There is no national statutory provision. However, Article 5ter of the Paris Convention applies.
6. The response refers to Article 33 of the Invention Law of the Democratic People’s Republic of Korea. However no express exception for private and non-commercial use is provided by statutory law.
7. Response was not provided. However, the exception is provided by Article 33(c) of the Invention Law of the Democratic People’s Republic of Korea.
8. There is no express statutory provision on prior use.
9. The response states that there is no such exception, but refers to government use for public health reasons.
10. The response refers to Section VII (New Plant Varities) of the Industrial Property Code of 2005.
11. The response refers to a future amendment of the legal framework.
12. Only exceptions relating to the farmers' use of patented inventions, no exception relating to the breeders' use of patented inventions.
13. While there is no prior use exception, a prior secret use constitutes a round for revocation of the patent.
14. The applicable type of exhaustion regime is uncertain.
15. International exhaustion is applied in relation to drugs and medicines, national exhaustion is applied for all other products.
16. The response refers to exceptions to plant variety protection.
17. While there is no government use exception, the response refers to the law regarding the expropriation of patents.
18. The response refers to exceptions available under the Seed Industry Act.
19. The response states that there are no such exceptions in patent protection, but refers to farmers' and breeders' use in plant variety protection.
20. The response refers to mechanisms in competition law.
21. The applicable type of exhaustion regime is defined according to the national laws of Contracting States.
22. Only compulsory licensing, government use exception is provided according to the national laws of Contracting States.
23. The response refers to compulsory licenses.
24. The exception applies to patents on plants and plant varieties only.
25. The response refers to Article 38 of Law No 9947.
26. The response refers to Article 15 of Qatar Decree Law No. (30), 2006.
27. The response refers to Article 11 of Qatar Decree Law No. (30), 2006.
28. The response refers to Section 26b of the Patent Act 57 of 1978.
29. There is no express statutory provision related to acts for obtaining regulatory approval from authorities. However, the exception is applied in case of obtaining an authorization to put a medicine or plant protection product on the market.
30. Please see 2 update which contains updated information related to experimental use and scientific research exception, as well as exception relating to acts for obtaining regulatory approval from authorities, submitted on June 28, 2013.
31. The response refers to sui generis system for protection of plant breeders' rights.
32. The response states that no such provisions exist under the Indian Patents Act, but refers to the Protection of Plant Varieties and Farmers' rights Act of 2001.
33. The response refers to plant variety protection under Law No. 20.247 on Seeds and Phytogenetic Creations.
34. The response states that for the exhibition purpose, exception to prior use is provided under the law.
35. Only government use exception.
36. The law does not provide an exception related to farmers' or breeders' use of patented inventions. The response references the Law on protection of Animal Breedings and Plant Varieties.
37. The response refers to The Protection of Plant Varieties and Farmers' Rights Act of 2001.
38. There is no statutory provision related to an exception for preparation of medicines. However, Article 53 of the Patents Act 1971 is relevant.
39. The response refers to plant breeders' rights under the National Seeds and Protection of Varieties Act of 2010.
40. The response refers to Section 13 of the Industrial Property Law 67/2008. However, the regulatory review exception is provided under Section 11(4)(a) of the Industrial Property Rights and their Enforcement for the Sultanate of Oman (Royal Decree No. 67/2008).
41.The Medicines and Allied Substances Act No.3 of 2013 provide for regulatory approval.